Autistic Brains Show Measurable Molecular Shift in Glutamate Signaling

For many autistic people, a crowded cafe isn’t just noisy. Every clinking spoon sounds like a bell. Every flickering light feels like a strobe. Clinicians have diagnosed autism through behavioral observation for decades, but the biological mechanisms behind these differences have remained elusive.

Now, researchers at Yale School of Medicine report a concrete molecular signature that sets autistic brains apart. The team found that autistic adults have about 15 percent fewer receptors for glutamate across nearly all brain regions. Glutamate is the brain’s primary excitatory neurotransmitter. The study appeared in The American Journal of Psychiatry.

The finding offers rare biological clarity in a field where diagnosis still relies almost entirely on watching how someone moves, speaks, and connects. It also supports a long-standing idea that autism involves an imbalance between excitatory and inhibitory signaling.

Linking Molecular Architecture to Electrical Activity

Neurons communicate by passing electrical signals and chemical messengers. Some signals excite nearby neurons and encourage them to fire. Others inhibit activity and act as a brake. Healthy brain function depends on keeping those forces balanced.

Scientists have long suspected that autism involves a shift in this balance, particularly in excitatory signaling driven by glutamate. But evidence has been indirect until now.

The Yale team studied 16 autistic adults and 16 neurotypical adults between ages 18 and 36. Each participant got both an MRI and a positron emission tomography scan. The MRI examined brain anatomy. The PET scan revealed molecular activity in living tissue. The PET scans focused on metabotropic glutamate receptor 5, or mGlu5. This receptor helps neurons respond when glutamate delivers its “go” signal.

Across all brain regions, autistic participants showed lower availability of mGlu5 receptors. The largest differences appeared in the cerebral cortex, which handles perception, decision-making, and social cognition.

To connect molecular findings to actual brain function, 15 autistic participants also got EEG tests. EEG measures electrical activity at the scalp. It provides a noninvasive window into how excitatory and inhibitory signals interact in real time.

Within the autistic group, lower mGlu5 availability tracked consistently with EEG patterns that reflected altered balance. Fewer glutamate receptors matched up with brain activity that suggested weaker excitatory signaling.

“We have found this really important, never-before-understood difference in autism that is meaningful, has implications for intervention, and can help us understand autism in a more concrete way than we ever have before,” James McPartland, PhD, Harris Professor of Child Psychiatry and Psychology at Yale, explains.

The connection between PET and EEG matters for clinics. PET scans are expensive and involve radiation exposure, which limits routine use. EEG is relatively cheap and widely available. “EEG isn’t going to completely replace PET scans, but it might help us understand how these glutamate receptors might be contributing to the ongoing brain activity in a person,” says Adam Naples, PhD, assistant professor in Yale’s Child Study Center and the study’s first author.

What Comes Next for Neurodivergent Medicine

The results don’t suggest that all autistic people need treatment or that autism should be “fixed.” Many neurodivergent individuals do not experience autism as a disability and may not want medical intervention. But for those whose symptoms interfere with daily life, the findings point to a specific biological system that could be targeted.

There are currently no medications that address the core difficulties associated with autism. By identifying mGlu5 as a brain-wide difference, the study opens the door to therapies aimed at this receptor, at least for some individuals.

The research also raises developmental questions. PET imaging has historically been limited to adults, so it remains unclear whether reduced mGlu5 availability contributes to autism early in life or emerges over time. With newer imaging techniques that reduce radiation exposure, the team hopes to study children and adolescents next.

“We want to start creating a developmental story and start understanding whether the things that we’re seeing are the root of autism or a neurological consequence of having had autism your whole life,” McPartland says.

For now, the work marks a shift in how autism can be understood. It’s not just a pattern of behaviors but a condition with a measurable molecular backbone inside the living human brain.

The American Journal of Psychiatry: 10.1176/appi.ajp.20241084